表紙
市場調查報告書

食道癌:開發中產品分析

Esophageal Cancer - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 229727
出版日期 內容資訊 英文 1233 Pages
訂單完成後即時交付
價格
Back to Top
食道癌:開發中產品分析 Esophageal Cancer - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 1233 Pages
簡介

食道癌是食道發病的癌症之一。主要的症狀有咳嗽和吞嚥障礙,胸部疼痛,壓迫感或加熱感,體重減少等。

本報告提供全球各國治療食道癌所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

食道癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

食道癌:企業開發中的治療藥

食道癌:大學/機關研究中的治療藥

食道癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

食道癌:企業開發中的產品

食道癌:大學/機關研究中的產品

食道癌的治療藥的開發企業

  • Adaptimmune Therapeutics Plc
  • Advantagene, Inc.
  • Advaxis, Inc.
  • Advenchen Laboratories, LLC
  • Almac Discovery Limited
  • Amgen Inc.
  • ArQule, Inc.
  • Array BioPharma Inc.
  • Aslan Pharmaceuticals Pte. Ltd.
  • ATLAB Pharma SAS
  • Bayer AG
  • Betta Pharmaceuticals Co. Ltd.
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Celldex Therapeutics, Inc.
  • Cellectar Biosciences, Inc.
  • Cerulean Pharma, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • Genmab A/S
  • Glycotope GmbH
  • Hutchison MediPharma Limited
  • Ignyta, Inc.
  • ImmunoFrontier, Inc.
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • Johnson & Johnson
  • Karyopharm Therapeutics, Inc.
  • Komipharm International Co., Ltd.
  • MacroGenics, Inc.
  • Mebiopharm Co., Ltd.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Omeros Corporation
  • Omnitura Therapeutics Inc.
  • Oncolys BioPharma Inc.
  • 小野藥品工業
  • Pfizer Inc.
  • Proteo, Inc.
  • Puma Biotechnology, Inc.
  • Shenzen SiBiono GeneTech Co., Ltd.
  • 鹽野義製藥
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Spectrum Pharmaceuticals, Inc.
  • Symphogen A/S
  • Synta Pharmaceuticals Corp.
  • 大鵬藥品工業
  • Taiwan Liposome Company, Ltd.
  • TaKaRa BIO
  • tella Inc
  • TG Therapeutics, Inc.
  • Transgene Biotek Limited
  • VioQuest Pharmaceuticals, Inc.
  • Virocan Therapeutics Private Limited

食道癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

食道癌:最近的開發平台趨勢

食道癌:暫停中的計劃

食道癌:開發中止的產品

食道癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11460IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer - Pipeline Review, H2 2019, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 69, 76, 4, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 4 and 3 molecules, respectively.

Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Esophageal Cancer - Overview
  • Esophageal Cancer - Therapeutics Development
  • Esophageal Cancer - Therapeutics Assessment
  • Esophageal Cancer - Companies Involved in Therapeutics Development
  • Esophageal Cancer - Drug Profiles
  • Esophageal Cancer - Dormant Projects
  • Esophageal Cancer - Discontinued Products
  • Esophageal Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Table 1: Number of Products under Development for Esophageal Cancer, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Table 9: Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Table 10: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 11: Products under Development by Companies, H2 2019
  • Table 12: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 13: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 14: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 15: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Table 16: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Table 17: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Table 18: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Table 19: Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Table 20: Products under Development by Companies, H2 2019 (Contd..9), H2 2019
  • Table 21: Products under Development by Companies, H2 2019 (Contd..10), H2 2019
  • Table 22: Products under Development by Companies, H2 2019 (Contd..11), H2 2019
  • Table 23: Products under Development by Universities/Institutes, H2 2019
  • Table 24: Number of Products by Stage and Target, H2 2019
  • Table 25: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Table 26: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Table 27: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
  • Table 28: Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
  • Table 29: Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019
  • Table 30: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 31: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Table 32: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Table 33: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
  • Table 34: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
  • Table 35: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
  • Table 36: Number of Products by Stage and Route of Administration, H2 2019
  • Table 37: Number of Products by Stage and Molecule Type, H2 2019
  • Table 38: Esophageal Cancer - Pipeline by AbbVie Inc, H2 2019
  • Table 39: Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2019
  • Table 40: Esophageal Cancer - Pipeline by ADC Therapeutics SA, H2 2019
  • Table 41: Esophageal Cancer - Pipeline by Aduro BioTech Inc, H2 2019
  • Table 42: Esophageal Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2019
  • Table 43: Esophageal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2019
  • Table 44: Esophageal Cancer - Pipeline by Agios Pharmaceuticals Inc, H2 2019
  • Table 45: Esophageal Cancer - Pipeline by Ambrx Inc, H2 2019
  • Table 46: Esophageal Cancer - Pipeline by amcure GmbH, H2 2019
  • Table 47: Esophageal Cancer - Pipeline by Amgen Inc, H2 2019
  • Table 48: Esophageal Cancer - Pipeline by AMI Onco Theranostics LLC, H2 2019
  • Table 49: Esophageal Cancer - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019
  • Table 50: Esophageal Cancer - Pipeline by Anhui Kedgene Biotechnology Co Ltd, H2 2019
  • Table 51: Esophageal Cancer - Pipeline by Apexigen Inc, H2 2019
  • Table 52: Esophageal Cancer - Pipeline by Apollomics Inc, H2 2019
  • Table 53: Esophageal Cancer - Pipeline by Aprea Therapeutics AB, H2 2019
  • Table 54: Esophageal Cancer - Pipeline by Ascenta Therapeutics Inc, H2 2019
  • Table 55: Esophageal Cancer - Pipeline by Ascentage Pharma Group International, H2 2019
  • Table 56: Esophageal Cancer - Pipeline by AstraZeneca Plc, H2 2019
  • Table 57: Esophageal Cancer - Pipeline by AVEO Oncology Inc, H2 2019
  • Table 58: Esophageal Cancer - Pipeline by Bayer AG, H2 2019
  • Table 59: Esophageal Cancer - Pipeline by BeiGene Ltd, H2 2019
  • Table 60: Esophageal Cancer - Pipeline by Bicycle Therapeutics Plc, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Esophageal Cancer, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top